The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes†
Abstract
Interleukin-28A (IL-28A), IL-28B and IL-29 are a family of class II cytokines that stimulate antiviral responses through a heterodimeric receptor that is distinct from the type I interferon (IFN) receptor. To better understand how this newly described family of cytokines regulates the antiviral state, we compared various cellular responses elicited by IL-29 and IFN-alpha. Here we show that these cytokines stimulate similar patterns of signal transducer and activator of transcription 1 (STAT-1), -2, -3, and -5 phosphorylation and nearly identical patterns of gene expression when analyzed in two distinct cell types by microarray analysis. Interestingly, the IL-29 receptor is preferentially expressed on primary hepatocytes within normal liver and pegylated forms of IL-29 and IFN-alpha induced equivalent 2'5' oligoadenylate synthetase (OAS) and MX1 gene expression in this cell type. Pegylated IL-29 also produced a significant reduction in human hepatitis B and hepatitis C viral load in vitro and reduced the cytopathic effect caused by the fully replicating flavivirus, West Nile virus. In conclusion, IL-29 and IFN-alpha stimulate identical antiviral responses despite their utilization of different receptors. This fact, combined with significant receptor expression in hepatitis virus-infected livers, suggests that IL-29 may have therapeutic value against chronic viral hepatitis in human patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Lauer, G. M., & Walker, B. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450107 · Cited by 2,973
Antiviral Actions of Interferons
Samuel, C. E. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.778-809.2001 · Cited by 2,743
IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex
Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H., & Donnelly, R. P. (2003) · Nature Immunology · doi:10.1038/ni875 · Cited by 1,868
Interferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,766
Panahi, M., Naderi, M., Morteza, T. S., & Parizadeh, S. M. J. (2007) · Cited by 1,722
IL-28, IL-29 and their class II cytokine receptor IL-28R
Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T. E., Kuestner, R., Garrigues, U., Birks, C., Roraback, J., et al. (2003) · Nature Immunology · doi:10.1038/ni873 · Cited by 1,570
Self-citationEfficient Initiation of HCV RNA Replication in Cell Culture
Blight, K. J., Kolykhalov, A. A., & Rice, C. M. (2000) · Science · doi:10.1126/science.290.5498.1972 · Cited by 1,412
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Marcellin, P., Lau, G. K. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.-M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040431 · Cited by 1,145
Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C., Lindsay, K., Payne, J., Dienstag, J. L., O'Brien, C., Tamburro, C., Jacobson, I. M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008023230503 · Cited by 840
Lok, A. S. F. (2002) · New England Journal of Medicine · doi:10.1056/nejm200205303462202 · Cited by 442
Lambda Interferon Inhibits Hepatitis B and C Virus Replication
Robek, M. D., Boyd, B. S., & Chisari, F. V. (2005) · Journal of Virology · doi:10.1128/jvi.79.6.3851-3854.2005 · Cited by 431
Side effects of α interferon in chronic hepatitis C
Dusheiko, G. (1997) · Hepatology · doi:10.1002/hep.510260720 · Cited by 397
Modulation of STAT signaling by STAT-interacting proteins
Shuai, K. (2000) · Oncogene · doi:10.1038/sj.onc.1203522 · Cited by 379
Bilsborough, J., Leung, D. Y. M., Maurer, M., Howell, M., Boguniewcz, M., Yao, L., Storey, H., LeCiel, C., Harder, B., & Gross, J. A. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.046 · Cited by 370
Self-citationInterferons and Other Cytokines
Hendrzak, J. A., & Brunda, M. J. (1997) · Cancer Therapeutics · doi:10.1007/978-1-59259-717-8_13 · Cited by 356
Biron, C. A. (1998) · Seminars in Immunology · doi:10.1006/smim.1998.0138 · Cited by 341
The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain
Donnelly, R. P., Sheikh, F., Kotenko, S. V., & Dickensheets, H. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0204117 · Cited by 289
Mihm, S., Fayyazi, A., Hartmann, H., & Ramadori, G. (1997) · Hepatology · doi:10.1002/hep.510250340 · Cited by 250
Self-citationThe metastasis associated protein S100A4: role in tumour progression and metastasis
Helfman, D. M., Kim, E. J., Lukanidin, E., & Grigorian, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602613 · Cited by 236
The iron metabolism of neoplastic cells: Alterations that facilitate proliferation?
Kwok, J. C., & Richardson, D. R. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00213-x · Cited by 215
A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist
Xu, W., Presnell, S. R., Parrish-Novak, J., Kindsvogel, W., Jaspers, S., Chen, Z., Dillon, S. R., Gao, Z., Gilbert, T., Madden, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171303198 · Cited by 212
Self-citationKorba, B. E., & Gerin, J. L. (1992) · Antiviral Research · doi:10.1016/0166-3542(92)90056-b · Cited by 189
SK HEP-1: A human cell line of endothelial origin
Heffelfinger, S. C., Hawkins, H. H., Barrish, J., Taylor, L., & Darlington, G. J. (1992) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/bf02631017 · Cited by 164
Deblandre, G. A., Marinx, O., Evans, S. S., Majjaj, S., Léo, O., Caput, D., Huez, G. A., & Wathelet, M. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23860 · Cited by 159
S100 proteins and their influence on pro-survival pathways in cancer
Emberley, E. D., Murphy, L. C., & Watson, P. H. (2004) · Biochemistry and Cell Biology · doi:10.1139/o04-052 · Cited by 140
Antiviral activity of hop constituents against a series of DNA and RNA viruses
Buckwold, V. E., WILSON, R., Nalça, A., Beer, B., Voss, T. G., Turpin, J. A., Buckheit, R. W., Wei, J., Wenzel-Mathers, M., WALTON, E., et al. (2003) · Antiviral Research · doi:10.1016/s0166-3542(03)00155-4 · Cited by 139
ISGF3γ p48, a specificity switch for interferon activated transcription factors
Bluyssen, H. A. R. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/1359-6101(96)00005-6 · Cited by 135
Vallat, L. D., Benhamou, Y., Gutierrez, M., Ghillani‐Dalbin, P., Hercher, C., Thibault, V., Charlotte, F., Pietté, J. C., Poynard, T., Merle‐Béral, H., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20594 · Cited by 112
Inhibition of proliferation by 1-8U in interferon-α-responsive and non-responsive cell lines
Brem, R., Oroszlan‐Szovik, K., Foser, S., Bohrmann, B., & Certa, U. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3016-9 · Cited by 43
Transcriptional profiling in hepatoblastomas using high-density oligonucleotide DNA array
Nagata, T., Takahashi, Y., Ishii, Y., Asai, S., Nishida, Y., Murata, A., Koshinaga, T., Fukuzawa, M., Hamazaki, M., Asami, K., et al. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00065-7 · Cited by 40
Fiorucci, G., Vannucchi, S., Chiantore, M. V., et al. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381729 · Cited by 25
Cited by
Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease
Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A., & Hymowitz, S. G. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101312 · Cited by 1,925
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Study, F. T. H. C., Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.447 · Cited by 1,826
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
The immunogenetics of Psoriasis: A comprehensive review
Harden, J. L., Krueger, J. G., & Bowcock, A. M. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.07.008 · Cited by 616
Interferon-λ: Immune Functions at Barrier Surfaces and Beyond
Lazear, H. M., Nice, T. J., & Diamond, M. S. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.001 · Cited by 480
Metadata
- Authors
- Doyle, S. E., Schreckhise, H., Khuu‐Duong, K., Henderson, K., Rosler, R., Storey, H., Yao, L., Liu, H., Barahmand‐pour, F., Sivakumar, P., Chan, C., Birks, C., Foster, D., Clegg, C. H., Wietzke‐Braun, P., Mihm, S., & Klucher, K. M.
- Venue
- Hepatology
- Published
- 2006-10
- Volume
- 44
- Issue
- 4
- Pages
- 896-906
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2068931925
- Cited by
- 348
- References
- 37
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.